SEC Company Response from Tvardi Therapeutics, (TVRD) — May 8, 2026
Tvardi Therapeutics, Inc.
Date: May 8, 2026 · CIK: 0001346830 · Accession: 0001104659-26-057883
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295496
Letter
Re: Tvardi Therapeutics, Inc.
TVARDI THERAPEUTICS, INC.
3 Sugar Creek Ctr. Blvd., Suite 525 Sugar Land. TX 77478 (713) 489-8654
May 8, 2026
Via EDGAR
U.S. Securities and Exchange Commission Division of Corporation Finance
Office of Information Technologies and Services 100 F Street, N.E. Washington, D.C. 20549
Registration Statement on Form S-3
File No. 333-295496
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the " Registrant ") hereby requests that the U.S. Securities and Exchange Commission (the " Commission ") take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-295496) (the " Registration Statement ") to become effective on Tuesday, May 12, 2026, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the " Staff "). The Registrant hereby authorizes Madison Jones of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones of Cooley LLP, counsel to the Registrant, at (202) 728-7087, or in her absence Divakar Gupta of Cooley LLP at (212) 479-6474.
Very truly yours,
TVARDI THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm TVARDI THERAPEUTICS, INC. 3 Sugar Creek Ctr. Blvd., Suite 525 Sugar Land. TX 77478 (713) 489-8654 May 8, 2026 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Information Technologies and Services 100 F Street, N.E. Washington, D.C. 20549 Re: Tvardi Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-295496 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the " Registrant ") hereby requests that the U.S. Securities and Exchange Commission (the " Commission ") take appropriate action to cause the Registration Statement on Form S-3 (File No. 333-295496) (the " Registration Statement ") to become effective on Tuesday, May 12, 2026, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter, or at such later time as the Registrant may orally request via telephone call to the staff of the Commission (the " Staff "). The Registrant hereby authorizes Madison Jones of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones of Cooley LLP, counsel to the Registrant, at (202) 728-7087, or in her absence Divakar Gupta of Cooley LLP at (212) 479-6474. Very truly yours, TVARDI THERAPEUTICS, INC. By: /s/ Dan Conn Name: Dan Conn Title: Chief Financial Officer cc: Madison Jones, Cooley LLP Divakar Gupta, Cooley LLP